UPenn Treats First Cancer Patients in Crispr-Based Trial
This article is for subscribers only.
Doctors at the University of Pennsylvania’s Abramson Cancer Center have infused two cancer patients with a Crispr-based medicine in another early human trial for the promising gene-editing technology.
Both patients’ cancers had relapsed before the start of the trial. One has multiple myeloma, and the other has sarcoma, Penn Medicine representative John Infanti said in an email. Funding for the trial is provided by Sean Parker’s Parker Institute for Cancer Immunotherapy and private firm Tmunity Therapeutics, he said.